Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tukysa
Pharma
Pfizer details Tukysa's 1st-line data in HER2 breast cancer
Addition of Tukysa to first-line maintenance therapy significantly reduced the risk of progression or death by 35.9%.
Angus Liu
Dec 10, 2025 8:15am
Pfizer scores again in HER2-positive breast cancer
Oct 14, 2025 12:33pm
Overall survival data blur Seagen's Tukysa-ADC path
Dec 6, 2023 8:15am
Seagen's breast cancer drug Tukysa boosts Roche's ADC
Aug 17, 2023 10:18am
Pfizer snaps up ADC cancer specialist Seagen for $43B
Mar 13, 2023 10:51am
Seagen's revenue up 25% in 2022 as growth drivers 'firing'
Feb 16, 2023 10:42am
